Vertaling van "reported cases with acute adverse effects " (Nederlands → Frans) :

Both the SCF’s 2003 opinion and the advisory report recently published by the German Federal Institute for Risk Assessment (BfR, 2008) mention a number of observation cases and reported cases with acute adverse effects, including death, in people who consume energy drinks.
L’avis du SCF de 2003 ainsi que l’avis récemment émis par l’Institut fédéral allemand d’évaluation des risques (BfR, 2008) mentionnent un certain nombre de cas d’observation et de cas rapportés signalant des effets nocifs aigus, comprenant des décès, chez des sujets consommant des boissons énergisantes.

Table 3: Update of evidence found in SR and HTA Search Radiation harms of mammography screening (40-49 y) questions Note Update of HTA (ETMIS) Date 03/05/2010 Keywords Breast neoplasms, mammography/ adverse effects, mass screening/ adverse effects Medline Case report.tw (156081) (OVID): 2 Letter.pt (689184) Filter 3 Historical article.pt (263481) RCT 4 Review of reported cases.pt (0) 5 Review,multicase.pt (0) 6 or/1-5 (1099551) 7 Breast/ or Breast Diseases/ (30731) 8 Neoplasms/ (216844) 9 7 and 8 (536) 10 exp Breast Neoplasms/ (171800) 11 (breast$ adj5 neoplas$).tw (2557) 12 (breast$ adj5 cancer$).tw (135752) 13 (breast$ adj5 carcin$).tw (31777) 14 (breast$ adj5 tumo$).tw (23441) 15 (breast$ adj5 metasta$).tw (16582) 16 (breast$ adj5 malig$).tw (7361) 17 exp Carcinoma, Ductal, Breast/ (8472) 18 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (207367) 19 Mammography/ae [Adverse Effects] (517) 20 Mass Screening/ae [Adverse Effects] (325) 21 19 or 20 (763) 22 18 and 21 (443) 23 22 not 6 (379) 24 limit 23 to (yr=" 2005 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (44) 25 from 24 keep 1-44 (44)
Table 5: Update of evidence found in SR and HTA Search Radiation harms of mammography screening (40-49 y) questions Note Update of HTA (ETMIS) Date 03/05/2010 Keywords Breast neoplasms, mammography/ adverse effects, mass screening/ adverse effects Medline Case report.tw (156081) (OVID): 2 Letter.pt (689184) Filter 3 Historical article.pt (263481) RCT 4 Review of reported cases.pt (0) 5 Review,multicase.pt (0) 6 or/1-5 (1099551) 7 Breast/ or Breast Diseases/ (30731) 8 Neoplasms/ (216844) 9 7 and 8 (536) 10 exp Breast Neoplasms/ (171800) 11 (breast$ adj5 neoplas$).tw (2557) 12 (breast$ adj5 cancer$).tw (135752) 13 (breast$ adj5 carcin$).tw (31777) 14 (breast$ adj5 tumo$).tw (23441) 15 (breast$ adj5 metasta$).tw (16582) 16 (breast$ adj5 malig$).tw (7361) 17 exp Carcinoma, Ductal, Breast/ (8472) 18 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (207367) 19 Mammography/ae [Adverse Effects] (517) 20 Mass Screening/ae [Adverse Effects] (325) 21 19 or 20 (763) 22 18 and 21 (443) 23 22 not 6 (379) 24 limit 23 to (yr=" 2005 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (44) 25 from 24 keep 1-44 (44)

Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete
Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete

At the end of 2007 the FAMHP initiated a programme for specific monitoring of new medicines (“black triangle” – symbol included in the BCFI-CBIP annotated drugs formulary – Gecommentarieerd Geneesmiddelenrepertorium – Répertoire Commenté des Médicaments) with the aim of encouraging healthcare professionals to report adverse effects of medicines with a new active substance to the FAMHP.
At the end of 2007 the FAMHP initiated a programme for specific monitoring of new medicines (“black triangle” – symbol included in the BCFI-CBIP annotated drugs formulary – Gecommentarieerd Geneesmiddelenrepertorium – Répertoire Commenté des Médicaments) with the aim of encouraging healthcare professionals to report adverse effects of medicines with a new active substance to the FAMHP.